Objective: To assess growth hormone (GH)/insulin like growth factor-1 (IGF-1) axis as a possible non-nutritional factor for growth retardation in children with cerebral palsy (CP).
Introduction
Cerebral palsy (CP) is a catastrophic acquired disease, occurring during development of the fetal or infant brain. It mainly affects the motor control centers of the developing brain, but can also affect cognitive functions, and is usually accompanied by a cohort of symptoms including lack of communication, epilepsy, and alterations in behavior. 1 Children with CP are generally undernourished and growth retarded in comparison with normal children, and the growth patterns of these children were associated with their overall health and social participation. CP children with best growth had fewest days of health care use and fewest days of social participation missed. 2 The reasons for poor growth are not only due to poor nutritional status, but also to non-nutritional factors such as immobility, endocrinological abnormalities, and spasticity with high energy requirements. 3 Growth hormone/insulin-like growth factor-1 axis: a possible non-nutritional factor for growth retardation in children with cerebral palsy
Measurement of growth hormone (GH)/insulin-like growth factor-1 (IGF-1) axis is frequently asked in growthretarded children, and IGF-1 is used during the assessment of a child for the presence of GH deficiency and to monitor the efficacy of GH replacement therapy. 4 The GH axis has not been systematically studied in children with CP, and the number of studies reporting whether or not GH secretion is impaired in CP is quite limited. 5, 6 However, there have been reports of abnormalities in GH secretion among these children. 7 Therefore, this study was designed to assess the GH-IGF-1 axis as a possible non-nutritional factor for growth retardation in children with CP.
Methods

Patient selection
This study was carried out at Mansoura University
Children's Hospital, Mansoura city, Egypt. Our study included 30 children (13 males and 17 females) with spastic CP of moderate severity (level III of the gross motor function classification system). 8 These children were subjected to thorough analysis, with full history taking, thorough examination, and all necessary laboratory and imaging investigation needed to confirm the diagnosis of idiopathic CP in each individual case, as patients were chosen from CP children who had sufficient follow-up time in our pediatric neurology outpatient clinic and not just from newly diagnosed cases. They were subsequently divided according to their growth status into children with normal growth parameters (CP-N group, seven children: three males and four females, with mean age of 1.89±0.57 years) and children with growth retardation (CP-R group, 23 children: 10 males and 13 females, with mean age of 1.86±0.48 years). CP children with growth retardation had either retarded height alone (only three children) or retarded both weight and height (20 children). Underweight and stunting were defined according to World Health Organization criteria (i.e., z score more than two standard deviations below the median weight and height for both age and gender). 9 All CP patients were non-breast feeders and were selected only if they had adequate oral food intake according to a 3-day diet recall given by an adult who usually spent most of the time with the child (generally the mother).
Recommendations about portion size, plates, spoons, and bottle were given to the proxy to mitigate information bias.
Food records were analyzed for energy and protein intake using the Egyptian nutrition food composition database, which contains information on 23 nutrients for 430 foods and 13 food groups. 10 The estimated intake was above 1,074 kcal/24 h (or 4,494 kJ/24 h) for energy intake and above 21 g/24 h for protein intake for every CP patient to be included in the study, in an attempt to exclude the nutritional factor that may be responsible for growth retardation. and patients with poor oral food intake or retention due to any cause (e.g. feeding problems, oral motor dysfunction, nasogastric or gastrostomy tube feeding, gastroesophageal reflux disease, and persistent vomiting or diarrhea) were also excluded from the study. Any CP or PEM case with history of prematurity, low birth weight, or intrauterine growth retardation was excluded from the study. PEM cases caused by or associated with any organic illness and not related to isolated or pure nutritional deficiency were not allowed to enter the study.
Anthropometric measurements
All children were subjected to anthropometric measurements, including weight for age, height for age, head circumference for age, mid-upper arm circumference, and weight for height. Standing height without shoes was measured by using a Harpenden stadiometer (Holtain Ltd).
Recumbent length was recorded in young children and in children with CP who were unable to stand on the scales using a digital supine measuring 
Determination of serum GH levels
Both basal GH level and GH level after stimulation, expressed in ng/mL, were determined in patients and controls by a solid phase, two-site chemiluminescent immunometric assay using an Immulite Autoanalyzer supplied by Siemens (USA).
Assay of serum IGF-1
Serum IGF-1, expressed in ng/mL, was determined in the same sample taken for basal GH assay using enzyme linked immunosorbent assay (ELISA). The materials were supplied by Diagnostic Systems Laboratories, Webster, TX, USA.
Sample size, power of the study, and statistical analysis
The sample size was calculated by the Epi-Info program.
The hypothesized mean and standard deviation of GH were 3.0 and 1.5 respectively. The null hypothesis mean was 2.0.
The confidence level and alpha error were set up at 95%
and 0.05 respectively. Beta error was set up at 0.20, so the power of the study was 80%. The estimated sample size was 25 infants in each group, but we increased the sample to 30 to guard against dropouts and defaulters.
Statistical analysis was done by using SPSS version 10. Qualitative data were expressed as numbers and percentages. Chi-square analysis with Yates correction was used as a test of significance for qualitative data.
The Kolmogorov-Smirnov test was used to determine the distribution of data. When the data were parametric, the F test (one-way ANOVA) was used for comparison of more than two groups and the t test for comparison of two groups. The Kruskal-Wallis H and Mann-Whitney U tests were used for comparison of nonparametric data from more than two groups and two groups respectively.
Spearman rank correlation was done to study the relation between variables. The Bonferroni test was used for correction of p values. Significance was considered at a p value of 0.05 or less.
Results
Demographic data and growth parameters of the studied subjects are summarized in Table 1 . (Table 2) . The group of PEM patients presented higher basal GH Table 3 ).
The group of PEM patients showed lower GH levels (Table 4) .
Correlation studies revealed insignificant data apart from a significant positive correlation between IGF-1 levels and height-for-age z score (r = 0.92, p < 0.001) in both CP groups and a significant negative correlation between gross motor function classification system and weight-for-age z score (r = -0.51, p = 0.01) in both CP groups.
Discussion
For many years, small size and low weight were accepted by clinicians as part of the child's disability in CP. However, every necessary effort should be done to overcome the problem of poor nutrition and growth retardation in CP patients. 13 Growth may be suboptimal in children with CP in spite of adequate dietetic management. Possible mechanisms may include abnormalities of the hypothalamicpituitary axis, psychosocial deprivation, and an interaction between suboptimal nutritional status and an abnormal central nervous system. 7 Therefore, we designed this work to assess GH-IGF-1 axis as a possible non-nutritional factor for growth retardation in children with CP.
In this study, the PEM group showed significantly higher insignificant difference was observed between the CP-N group or the CP-R group and normal controls. This was evident in other studies where basal GH level was significantly higher in malnourished patients than in controls. 14, 15 Moreover, this points out that our selected CP patients, whether in CP-N or CP-R group, may not be suffering from overt or severe nutritional deficiency, like malnourished patients are, otherwise they would have high basal GH levels similar to those of PEM patients, or there may be an element of subnormal pituitary response to nutritional deficiency in CP children that leads them to behave more closely to normal controls in this respect.
After the insulin stimulation test, the CP-R group had significantly lower GH values compared to the REF group Regarding IGF-1 values, we found significantly lower IGF-1 levels in CP-R children compared to normal controls, which was also observed in other studies 1, [17] [18] [19] where CP in children was associated with lower IGF-1 levels. Moreover, similarly to other studies, 20 significantly lower IGF-1 levels were observed in the PEM group compared to controls.
The decrease in protein and energy intake, adipose tissue, and serum IGF-1 levels in children with PEM may result in decreased leptin secretion, which may initiate food intake by increasing appetite and stimulating the secretion of cortisol and GH, with significant elevation of basal GH levels. 15 Furthermore, our findings were supported by Hayashi et al., 21 who reported that spastic type CP patients showed subnormal responses to GH releasing factor, although their somatomedin C was normal, and concluded that spastic type CP was associated with reduced pituitary reserve of GH. In addition, GH therapy enhanced growth of a stunted female child with CP even without documented GH deficiency; thus, GH treatment might be beneficial for children with CP. 6 This study showed some discrepancy between GH and IGF-1 levels. The group of PEM patients had higher basal GH levels in spite of having significantly lower IGF-1 levels compared to CP-N and REF groups. Similarly, the CP-R group had a lower IGF-1 level than the CP-N group, without significant difference between both groups in regard to basal or stimulated GH levels. This discrepancy may be explained if we consider the different factors that regulate IGF-1 expression, including hormonal influence (GH), 22 tissue responsiveness to GH, 23 and nutritional factors. 24 Malnutrition-induced peripheral GH resistance may be responsible, at least partially, for reduced IGF-1 levels in PEM patients. In addition, nutritional status is a critical factor that modulates the responsiveness of the tissues, especially the liver, to GH and the resulting production of IGF-1. 25 Therefore, IGF-1 levels of the CP-N group and normal controls were almost similar, which may be related to better nutritional status and more adequate food intake in the CP-N group than in the CP-R group, while those of CP-R and PEM groups were also similar, most probably due to underlying coexistent significant nutritional deficiency in the CP-R group that remained unrecognized and resembled the condition of pure nutritional deficiency in patients with PEM. Although we tried to include CP patients with estimated energy and protein intakes above the recommended daily allowances of energy and protein for children aged 1-3 years to exclude the nutritional factor for growth retardation, it seemed that CP-R patients had coexistent nutritional deficiency, which may be explained by a possible overestimation of food intake by their parents, as we relied on a 3-day diet recall to estimate energy and protein intake. This was also observed in other studies showing that parents' perception of their CP child's nutrition was usually not as accurate as they thought. 26 Finally, it is worth to mention that our study is unique with respect to assessment of GH/IGF-1 axis as a possible non-nutritional factor for growth retardation in young children below 2 years of age with CP in comparison to PEM children who presented a model for growth retardation related to isolated nutritional deficiency.
This allowed us to see the difference in GH/IGF-1 axis between groups more clearly and better than if this axis was studied in CP children compared to healthy controls alone. So, if growth retardation in CP was related only to nutritional factors, the changes in GH/IGF-1 axis would have been exactly the same as in the PEM group, but the differences observed between CP and PEM children pointed to abnormalities in this axis.
Conclusions
CP-R patients failed to demonstrate the same high basal GH response as PEM patients and responded inadequately to the insulin stimulation test, but they had IGF-1 levels comparable to those of PEM patients. On the other hand, CP-N patients behaved as normal controls regarding their basal GH and IGF-1 levels, but failed to respond to the insulin stimulation test as adequately as normal controls.
The PEM group presented high basal GH and low IGF-1 levels. These findings suggest non-nutritional factors as contributing factors for growth retardation in CP children and may promote further widespread multicenter trials that use GH or IGF-1 to help in the management of growth retardation in children with CP, which can certainly improve their overall health status.
